Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
At the time the article was last revised Henry Knipe had the following disclosures:
- Integral Diagnostics, Shareholder (ongoing)
- Micro-X Ltd, Shareholder (ongoing)
These were assessed during peer review and were determined to not be relevant to the changes that were made.View Henry Knipe's current disclosures
Anti-synthetase syndrome is a systemic, inflammatory, autoimmune disease that is characterized by inflammatory myositis, polyarthritis associated with interstitial lung disease, and anti-synthetase autoantibodies.
Anti-synthetase syndrome can result from autoantibodies to eight of the aminoacyl-transfer RNA synthetases. These include:
anti-JO-1: most common anti-synthetase autoantibody
anti-PL7 / anti-threonyl-tRNA synthetase
anti-Ro52 / anti-Ro52-positive antisynthetase syndrome (ASS)
Imaging findings vary depending on the organ involved.
The associated interstitial lung disease of anti-synthetase syndrome may usually give either a NSIP pattern, an organizing pneumonia (OP) pattern or a combination of the two (NSIP-OP pattern) 6. A UIP pattern may also occasionally occur 8. The consolidative regions may decrease or resolve in many cases although the disease can at times progress to fibrosis in more than one third of patients.
Treatment and prognosis
Medications used for anti-synthetase syndrome include corticosteroids, azathioprine, mycophenolate mofetil (MMF), calcineurin inhibitors (tacrolimus and cyclosporine), rituximab, cyclophosphamide and intravenous immunoglobulin (IVIG) 9.